Deliver more value across the system

In our new era of outcomes-based healthcare, the success of a single biopharma company increasingly depends on the success of the entire system. Only by solving for population health goals alongside other healthcare stakeholders can biopharma be rewarded for innovation. In Value to outcomes 2.0, we explore 10 interdependent trends that are shaping how product value and patient outcomes can be optimized across the global healthcare system.

Scroll down to learn about each trend, or download the full paper now.

Rise in Healthcare

1. Accelerating growth in healthcare spending drives demand for pricing transparency

As healthcare spending rises, policy makers, insurers and healthcare technology companies are examining new cost containment approaches. Prescription drug spending has come under particular scrutiny. Even for highly innovative specialty products such as hepatitis C or cancer therapies, price is increasingly driving formutary decisions and competitive strategies.
Download our white paper


2. The volume-to-value trifecta: Purchasing, pricing and premiums

The marketplace is steadily advancing toward a value-based reality. The federal government is testing alternative drug payment designs to further the goal of more efficient spending to achieve quality care. Drug prices are reflecting not merely features and patient benefits but also cost effectiveness and healthcare system performance. And payers are shifting economic risk to consumers by applying value-based decision-making to their insurance product design.
Download our white paper


3. Lean healthcare: Matching promise with reality

From eliminating overuse and misuse of tests to cutting contracting cycle times to reducing the number of "low-value" services to beneficiaries, healthcare stakeholders are taking waste out of the system. This push for leaner healthcare is coupled with pressure to use outcomes-based evidence to drive cost-effective service offerings. Efficiency-generating mergers between large payers are contributing to a reconfigured health insurance industry.
Download our white paper


4. Streamlined regulatory and reimbursement pathways to optimize patient access

Alternate legal and clinical design approaches are helping to speed drugs to appropriate populations. State right-to-try laws, plus an accelerated FDA expanded access program, are giving terminally ill patients quicker access to experimental therapies. Adaptive trial designs and master protocols are taking advantage of complex statistical methodologies to characterize drug efficacy and safety more precisely and to test multiple drugs in the same trial.
Download our white paper

Accelerating players

5. Real-world evidence underpinning value-based healthcare: "Just prove it"

Multiple types of data, collected from multiple sources and aggregated from multiple sectors of the healthcare system, are reshaping our idea of a drug's effectiveness. Augmenting randomized clinical trial data, real-world evidence is supporting regulatory approval while giving a more comprehensive picture of outcomes. Biopharma companies and payers are partnering more often to demonstrate product value in innovative ways.
Download our white paper


6. The dichotomy of big data: Reconciling individualized intervention with population health goals

Big data solutions are empowering biopharma to collect, analyze and apply real-world evidence like never before. These expanded capabilities are helping to match patient-level needs to systemwide efficiency and cost savings. Nevertheless, information integration still needs to increase for healthcare stakeholders to reach their professed goal of true patient centricity.
Download our white paper


7. "Globalization" of market access: A ground game to optimize patient access

Regulatory changes are introducing new patients into the healthcare system as well as creating new demands for better value demonstrations. In the U.S., millions of uninsured are now receiving coverage, while reimbursement payments are being tied to quality measures. In Europe, a fragmented payer landscape is amplifying the need to define value locally.
Download our white paper

Minding gaps

8. Patient centricity: A unifying theme for all stakeholders

Providers are operating medical practices as patient-centered medical homes. Pharmacies are incentivizing patients to share their data. Regulators are calling for more patient-centric risk-benefit assessments. Biopharma companies are designing more patient-centered trials. In the middle of all this activity, patients are demanding more consumer-focused messaging.
Download our white paper


9. Technology enabling the democratization of research

Digital technologies are fundamentally changing the way patients collect and share their healthcare data. Wearable devices may help researchers recruit subjects and help participants complete informed consent and answer research surveys. Vast amounts of human DNA data are being stored on cloud computing systems, while cellular- enabled solutions can link provider teams and family members to help treat patient conditions such as diabetes.
Download our white paper


10. Public health innovation: Biopharmaceuticals lost in translation?

The opportunity now exists to boost human health worldwide. Achieving this grand goal will take new definitions of public health success and new outcome measures that include social equity. In addition, a more effective global architecture needs to be created for monitoring and mitigating infectious disease threats, potentially saving millions of lives. To contribute, biopharma will need to realign its drug development pipeline, collaborate for greater innovation, and re-engineer its approaches to meet public health needs.
Download our white paper

Sources for infographics

1. Luhby, T. (2015, July 28). Health cart spending expected to grow faster. CNN Money.
2. American Association for Physician Leadership. (2015, April 4). The value of physician leadership survey results.
3. Reinke, T. (2015, October). CMS takes the lead in oncology payment reform. Managed Care.
4. Quintiles. The New Health 2012 Report: Rethinking the Risk Equation in Biopharmaceutical Medicine. May 2012.
7. Tu T., Muh1estei'l 0., et a1. (2015, May 12). The Impact of accountable care: origins and future of accountable care organizations. Brookings
9. Edney. A., & Chen, C. (2015. September 15). Drug companies using wearables on patients. Bloomberg.